Generics, Biosimilars Sustainability Still at Risk

By Gina ShawGenerics and biosimilars continue to deliver extraordinary savings across the U.S. healthcare system—$467 billion in 2024 alone—according to the 2025 U.S. Generic & Biosimilar Medicines Savings Report from the Association for Accessible Medicines (AAM) and the IQVIA Institute for Human Data Science. But the report also warns that without targeted reforms to ensure market stability and faster adoption, those savings may not be sustainable.“How … are drug p